Juan Bergua
109 Papers
260 Citations
Juan Bergua is an academic researcher. The author has contributed to research in topics: Medicine & Acute promyelocytic leukemia. The author has an hindex of 26, co-authored 90 publications.
Chat about Author
Papers
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
María P. Martínez Sánchez,Juan Eduardo Megías-Vericat,Rebeca Rodríguez-Veiga,Susana Vives,Juan Bergua,Anna Torrent,Sara Suarez-Varela,Blanca Boluda,Joaquin Martinez-Lopez,Isabel Cano-Ferri,Evelyn Acuña-Cruz,Laura Torres-Miñana,Beatriz Martín-Herreros,Alfons Serrano,Amparo Sempere,Eva Barragán,Claudia Sargas,Miguel A. Sanz,David Martínez-Cuadrón,Pau Montesinos +19 more
TL;DR: In this article, the safety and preliminary clinical activity of selinexor, an oral exportin-1 (XPO1) inhibitor, in combination with FLAG-Ida in younger R/R acute myeloid leukemia (AML) patients were evaluated.
10
Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols
Cristina Motlló,Josep-Maria Ribera,Mireia Morgades,Isabel Granada,Pau Montesinos,Salut Brunet,Juan Bergua,Mar Tormo,Raimundo García-Boyero,Josep Sarrá,Eloy del Potro,Carlos Grande,Pere Barba,Teresa Bernal,María-Luz Amigo,Javier Grau,José Cervera,Evarist Feliu +17 more
TL;DR: Specific treatment approaches are required to improve the outcome of patients with KMT2A-rearrangements, and a trend for a longer CR duration was observed in patients undergoing HSCT vs those receiving chemotherapy.
10
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Josep-Maria Ribera,Olga García,Cristina Gil,Santiago Mercadal,Irene García-Cadenas,Pau Montesinos,Pere Barba,Susana Vives,José González-Campos,Mar Tormo,Jordi Esteve,Aurelio López,maria Jose Moreno,Jordi Ribera,Natalia Alonso,Arancha Bermúdez,Maria Luz Amigo,Eulàlia Genescà,Daniel García,Ferran Vall-Llovera,Juan Bergua,Ramon Guardia,María Carmen Monteserín,Teresa Bernal,María Calbacho,María Pilar Martínez,Evarist Feliu +26 more
TL;DR: Compared with less intensive chemotherapy, pediatric-inspired intensive chemotherapy significantly improves the outcome of older adults with Ph-negative ALL in the age range of 55-65 years.
9
Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial Including the Use of Propensity Score (PS) Method to Reduce Assignment Bias.
Josep-Maria Ribera,Albert Oriol,Mireia Morgades,Miguel-Angel Sanz,Pau Montesinos,Josep Sarrá,Salut Brunet,Pascual Fernández-Abellán,Ramon Guardia,Jordi Esteve,José González-Campos,Arancha Bermúdez,María-José Moreno,Maria-Teresa Bernal,Mar Tormo,Eloy del Potro,Antonia Cladera,Andreu Llorente,Raimundo García-Boyero,Maria-Jose Rabuñal,Juan Bergua,Carlos Grande,María-Luz Amigo,Javier Bueno,Concepción Bethencourt,Jesús María Hernández-Rivas,Evarist Feliu +26 more
TL;DR: The results suggest that in HR Ph- adult ALL pts with adequate response to induction and adequate clearance of MDR after consolidation the results of therapy are not hampered by avoiding allogeneic SCT.
9
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Rosa Ayala,Gonzalo Carreño-Tarragona,Eva Barragán,Blanca Boluda,María José Larrayoz,María C. Chillón,Estrella Carrillo-Cruz,Cristina Bilbao,Joaquin Sanchez-Garcia,Teresa Bernal,David Martínez-Cuadrón,Cristina Gil,Josefina Serrano,Carlos Rodríguez-Medina,Juan Bergua,José A. Pérez-Simón,María Calbacho,Juan-Manuel Alonso-Domínguez,Jorge Labrador,Mar Tormo,María-Luz Amigo,Pilar Herrera-Puente,I. Rapado,Claudia Sargas,Iria Vázquez,María José Calasanz,T. Gomez-Casares,Ramón García-Sanz,Miguel A. Sanz,Joaquin Martinez-Lopez,Pau Montesinos +30 more
TL;DR: In this paper , the prognostic impact of the FLT3-ITD allele ratio (AR) is investigated in acute myeloid leukemia (AML) patients with PETHEMA protocols.